br GmbH BMS Boehringer Ingelheim Italia S p A
GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine; at the end, she has received research funding from the following organizations: AIRC, AIFA, Italian Moh, TRANSCAN. GLR declares travel accommodations and honoraria with AstraZeneca, MSD International GmbH, BMS, Eli Lilly. All other authors have no relevant conflicts of interest to disclose.
The authors want to thank Peter Head for his valuable support in medical writing assistance.
 A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello, J. von Pawel, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet 389 (2017) 255–265.
 M.C. Garassino, A.J. Gelibter, F. Grossi, R. Chiari, H. Soto Parra, S. Cascinu, et al., Italian nivolumab expanded access program in nonsquamous non–small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients. A multicentric experience, J. Thorac. Oncol. 13 (2018) 1146–1155.
 G. Fucà, G. Galli, M. Poggi, G. Lo Russo, C. Proto, M. Imbimbo, et al., Low baseline serum sodium concentration is associated with poor clinical outcomes in metastatic Non-Small Cell Lung Cancer patients treated with immunotherapy, Target. Oncol. 13 (2018) 795–800.
 G. Fucà, G. Galli, M. Poggi, G. Lo Russo, C. Proto, M. Imbimbo, et al., Modulation of peripheral blood immune Okadaic acid by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors, ESMO Open 4 (2019) e000457.
Contents lists available at ScienceDirect
Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer
James C. Cripe a, , Tommy R. Buchanan Jr a, Lindsay M. Kuroki a, Leping Wan a, Kathryn A. Mills a, Leslie Massad a, Andrea R. Hagemann a, Katherine C. Fuh a, David G. Mutch a, Matthew A. Powell a, Koji Matsuo b, Premal H. Thaker a
a Washington University School of Medicine St. Louis, St Louis, MO, USA
b Keck School of Medicine of USC, Los Angeles, CA, USA
• We describe the relationship of BMI with menopausal symptoms in women undergoing oophorectomy for endometrial cancer.
• Women with a BMI N40 had significantly less menopausal symptoms than women with BMI b30.
• Menopausal symptom type did not differ in relation to BMI.
• These data have not been previously documented and may impact preoperative counseling of patients.
Objectives. Premenopausal women may undergo surgical menopause after staging for their endometrial can-cer. Our aim was to determine the association between body mass index (BMI) and surgical menopausal symp-toms.
Methods. We report a retrospective review of endometrial cancer patients whom underwent menopause sec-ondary to their surgical staging procedure. Symptoms were classified as severe if treatment was prescribed, or mild if treatment was offered, but declined. Univariate analysis was performed with ANOVA and Chi-square tests as appropriate. Relative risks (RR) were generated from Poisson regression models.
Conclusions. Women younger than 50 with BMI N40 and stage I endometrial cancer are significantly less likely than women with BMI b30 to experience menopausal symptoms after oophorectomy. This information may assist in peri-operative counseling.
The incidence of endometrial cancer has increased by N50% over the last ten years and will affect a projected 63,230 women in 2018 . This steady upward trend is partially related to the increasing obesity
Corresponding author at: Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.
E-mail address: [email protected] (J.C. Cripe).
epidemic affecting 36.5% of adults in the United States . Not only is endometrial cancer more common, but also it is affecting premeno-pausal women more frequently . The 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system includes surgical removal of uterus, tubes, and ovaries with lymphadenectomy indicated depending on pre-operative and intra-operative findings . Ovarian conservation remains contro-versial despite several national database studies suggesting this does not adversely affect survival in women with early stage endometrial
cancer [5–7]. Given the rising prevalence of endometrial cancer among premenopausal women, surgical menopause is becoming increasingly problematic when caring for these women.